Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
LONDON - Morgan Stanley & Co. International plc has exercised in full the over-allotment option to acquire 33,042,453 additional ordinary shares of Verisure plc at the offer price of €13.25 per share, according to a stabilization notice released Thursday.
The over-allotment option was exercised on behalf of the underwriters from Aegis Lux 2 S.à r.l. Following this action, the stabilization period, which was initially expected to end on November 7, has been terminated effective immediately.
The announcement noted that no stabilization activities were undertaken by Morgan Stanley, which served as the stabilization manager for the offering.
Verisure’s initial public offering consisted of 220,283,021 ordinary shares at €13.25 per share, excluding the over-allotment option and subscriptions. The shares trade under the ISIN code GB00BVMN1558.
The company’s shares were initially offered on October 8, 2025, when the pre-stabilization period was announced.
The information was provided through a regulatory news service announcement from the London Stock Exchange, which noted that the securities have not been registered under the United States Securities Act and are not being offered in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.